Trebicka Jonel, Wix Cyrus, von Heydebrand Matthias, Hittatiya Kanishka, Reiberger Thomas, Klein Sabine, Schierwagen Robert, Kristiansen Glen, Peck-Radosavljevic Markus, Fischer Hans-Peter, Møller Søren, Bendtsen Flemming, Krag Aleksander, Sauerbruch Tilman
Department of Internal Medicine I, University of Bonn, Bonn, Germany; Gastrounit, Medical Division, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark.
Liver Int. 2015 Apr;35(4):1393-402. doi: 10.1111/liv.12613. Epub 2014 Jul 5.
BACKGROUND & AIMS: Patients with cirrhosis display hypocontractility of splanchnic vessels because of dysregulation of vasoactive proteins, such as decreased effect of RhoA/ROCK and increased activity of β-Arrestin-2 and eNOS. However, it is unknown whether the dysregulation of vasoactive proteins is displayed in other vessels. We investigated whether expression of vasoactive proteins can be evaluated in gastric mucosa vessels.
Biopsies from the gastric mucosa of 111 patients with cirrhosis were collected at three different centres and from 13 controls. Forty-nine patients had received TIPS. Portal pressure gradient was measured in 49 patients with TIPS and in 16 patients without TIPS. Biopsies from the antrum were conserved in formaldehyde for immunohistochemistry or shock-frozen for PCR and Western blot.
The mucosal transcription of vascular markers (αSMA, CD31) was higher in cirrhotic patients than controls, which was confirmed by immunohistochemistry. On average, relative mucosal levels of RhoA and ROCK were lower, while β-Arrestin-2 levels were higher in cirrhotic patients compared to controls. Transcriptional levels of eNOS increased with presence of ascites and grade of oesophageal varices. Patients with TIPS showed less pronounced markers of vascular dysfunction in gastric mucosa.
This is the first evidence that the expression of vasoactive proteins in mucosa from the gastric antrum of patients with cirrhosis reflects their vascular dysfunction and possibly changes after therapeutic interventions.
肝硬化患者内脏血管收缩功能减退,这是由于血管活性蛋白调节异常所致,如RhoA/ROCK效应降低,β - Arrestin - 2和eNOS活性增加。然而,血管活性蛋白的调节异常是否在其他血管中也存在尚不清楚。我们研究了是否可以在胃黏膜血管中评估血管活性蛋白的表达。
在三个不同中心收集了111例肝硬化患者胃黏膜活检组织以及13例对照的活检组织。49例患者接受了经颈静脉肝内门体分流术(TIPS)。对49例接受TIPS的患者和16例未接受TIPS的患者测量门静脉压力梯度。胃窦活检组织用甲醛固定用于免疫组织化学检查,或速冻用于PCR和蛋白质印迹分析。
免疫组织化学证实,肝硬化患者血管标志物(αSMA、CD31)的黏膜转录水平高于对照组。平均而言,与对照组相比,肝硬化患者RhoA和ROCK的相对黏膜水平较低,而β - Arrestin - 2水平较高。eNOS的转录水平随腹水的出现和食管静脉曲张程度增加。接受TIPS的患者胃黏膜血管功能障碍标志物表现不明显。
这是首个证据表明肝硬化患者胃窦黏膜中血管活性蛋白的表达反映了其血管功能障碍以及治疗干预后的可能变化。